Metropolis Healthcare Limited reported earnings results for the fourth quarter and full year ended March 31, 2025. For the fourth quarter, the company reported sales was INR 3,452.92 million compared to INR 3,310 million a year ago. Revenue was INR 3,522.62 million compared to INR 3,335.39 million a year ago. Net income was INR 291.42 million compared to INR 364.07 million a year ago. Basic earnings per share from continuing operations was INR 5.69 compared to INR 7.11 a year ago. Diluted earnings per share from continuing operations was INR 5.69 compared to INR 7.08 a year ago.
For the full year, sales was INR 13,312.03 million compared to INR 12,077.09 million a year ago. Revenue was INR 13,463.16 million compared to INR 12,168.26 million a year ago. Net income was INR 1,449.68 million compared to INR 1,278.16 million a year ago. Basic earnings per share from continuing operations was INR 28.29 compared to INR 24.95 a year ago. Diluted earnings per share from continuing operations was INR 28.15 compared to INR 24.87 a year ago.
Metropolis Healthcare Limited is an India-based company, which is engaged in providing diagnostic services patients, healthcare providers, and corporates across India and Africa. The Company has a single operating segment, namely Pathology service. It is mainly engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company serves both the business-to-business (B2B) and business-to-customer (B2C) markets. It has approximately 199 clinical laboratories across 22 states in India. Its subsidiaries include Amin's Pathology Laboratory Private Limited, Ekopath Metropolis Lab Services Private Limited, Centralab Healthcare Services Private Limited, Metropolis Histoexpert Digital Services Private Limited, among others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
